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Platelet function is modiﬁed by common sequence
variation in megakaryocyte super enhancers
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Linking non-coding genetic variants associated with the risk of diseases or disease-relevant traits
to target genes is a crucial step to realize GWAS potential in the introduction of precision med-
icine. Here we set out to determine the mechanisms underpinning variant association with platelet
quantitative traits using cell type-matched epigenomic data and promoter long-range interactions.
We identify potential regulatory functions for 423 of 565 (75%) non-coding variants associated
with platelet traits and we demonstrate, through ex vivo and proof of principle genome editing
validation, that variants in super enhancers play an important role in controlling archetypical
platelet functions.
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lood cells traits such as counts and mean cellular volumes
are highly heritable and can be readily measured using
hematology analysers as part of a complete blood count
(CBC). We identiﬁed, by genome-wide association study
(GWAS), 2,706 independent sentinel variants associated with 36
CBC-measured traits of blood cells1. Of these variants, 674 are
associated with the count, the mean volume, the width of the
volume distribution or the mass (also known as crit,
countmean volume) of platelets (CBC-P hereafter). Platelets
are the smallest cells of the blood and their functions are to
initiate repair at sites of vascular injury and to maintain
haemostasis; furthermore, they are implicated in the aetiologies
of myocardial infarction and stroke, among the leading causes of
morbidity and mortality worldwide.
Platelets and red cells are formed by megakaryocytes (MKs)
and erythroblasts (EBs), which originate through a stepwise
differentiation of the haematopoietic stem cell (HSC)2. Red cell
production depends on iron homeostasis3 and oxygen sensing3,
whereas platelet production is controlled by a negative feedback
loop. This is based on circulating thrombopoietin level, which is
directly linked to platelet count, because platelets bind and
degrade thrombopoietin via its receptor myeloproliferative
leukemia protein (MPL) on their surface4. Platelets and MKs
therefore provide an excellent model to link trait-associated
variants to the genes they may regulate.
The majority of CBC-P-associated variants are located in the
non-coding genomic space and therefore it remains challenging
to explain their mechanism of action. GWAS signals are enriched
in enhancer elements5. Enhancers function through chromatin
loops, physically connecting them with the promoters of their
target gene(s)6,7 often bypassing the nearest gene8. Here, to
determine the mechanisms underpinning variant association with
platelet quantitative traits, we integrate MK and EB promoter
capture Hi-C (PCHi-C)9, a core set of histone modiﬁcations and
CCCTC-binding factor (CTCF)-binding data generated as part of
this and the BLUEPRINT consortium studies10,11. We propose a
mapping strategy able to identify potential regulatory functions
for 423 of 565 (75%) of CBC-P non-coding variants. Moreover,
we provide examples of the effect of common variation on
transcriptional mechanisms, which reveal that CBC-P in MK
super enhancers (SEs) modify platelet functions.
Results
MK and EB open chromatin dynamics. Most associations
between variants and traits are limited to a single type of blood
cell; for example, only 41 of the 674 (6.1%) CBC-P-associated
sentinel variants are pleiotropic, that is, also associated with red
cell traits1. Earlier studies suggest that this restriction of
associations to a single-cell lineage is in part explained by
associated variants being located in cell-type-speciﬁc open
chromatin elements12–15.
To further characterize the lineage restriction of the CBC-P
associations we generated open chromatin maps for the different
stages of MK differentiation: HSCs, common myeloid progenitors
(CMPs), MK–EB progenitors (MEPs) and MKs, as well as
EBs (Supplementary Fig. 1). We found that 87.7% (110,844
of 126,428) of open chromatin regions in MKs fell into
four categories (Fig. 1a, Supplementary Fig. 2 for EBs and
Supplementary Data 1). The ﬁrst (category I) contained open
chromatin regions present from HSCs through to MKs and EBs.
Category II comprised elements that were open throughout
differentiation, but were closed in EBs, whereas categories III and
IV consisted of elements that opened during the ﬁnal stage of
differentiation, either only in MKs (III) or in both MKs and EBs
(IV). To identify the genes regulated by these elements, we used
PCHi-C data16 (Supplementary Fig. 3, Supplementary Table 1
and Supplementary Data 2). We experimentally determined the
genomic loci occupied by CTCF, a structural protein involved in
the establishment of DNA loops17, in MKs and EBs, and found
that promoter-interacting fragments have higher density of
bound CTCF than the rest of the genome (Po2.2 10 16,
zero-inﬂated negative binomial test); this was the case both when
CTCF peaks were located in open chromatin or outside open
chromatin regions (in both cases, Po2.2 10 16, negative
binomial test, Supplementary Table 2). Moreover, we found
that open chromatin density is higher in promoter-interacting
fragments (Po2.2 10 16, zero-inﬂated negative binomial test,
Supplementary Table 2) as are chromatin modiﬁcations16.
Gene Ontology (GO) terms enrichment analysis for genes
interacting with open chromatin elements in any of the four
categories described above revealed terms related to platelet
functions interspersed among more generic terms relating to
cellular metabolism and processes (Supplementary Data 3),
indicating that the key cellular functions of platelets and red
cells are not controlled solely by elements activated late in
differentiation (Categories III and IV). We investigated whether a
more meaningful enrichment of GO terms could be observed by
assigning function to the MK and EB genomes according to their
epigenetic state. Analysis of the data generated by the BLUE-
PRINT consortium for six histone marks with the IDEAS18
chromatin segmentation algorithm showed that the majority of
segments had the same epigenomic state in MKs and EBs
(Supplementary Fig. 4). Less than 20% of the genomic space
labelled as ‘enhancer’ in either MKs or EBs had a different state in
the other cell type, with ‘weak enhancer’ being the most frequent
state transition (Supplementary Fig. 4).
MK and EB regulatory landscape. Considering these results, we
further explored differences between MKs and EBs that could
explain their distinct transcriptomes. To highlight possible dif-
ferences in enhancers’ activity we compared the strength of
H3K27ac signals between MKs and EBs, and identiﬁed just
12,047 (17.5%) elements that differed signiﬁcantly, with 5,237 and
6,810 preferentially acetylated in MKs and EBs, respectively
(twofold change, 0.05 false discovery rate; Fig. 1b and
Supplementary Data 4). Analysis of BLUEPRINT RNA sequen-
cing data identiﬁed 1,546 genes differentially expressed
between MKs and EBs (Fig. 1c, estimated fold change 42,
posterior probability for differential expression 40.5,
Supplementary Data 5). We then analysed PCHi-C interaction
data and found that enhancers with higher acetylation levels in
MKs were enriched for interactions with MK upregulated genes
(Fisher’s exact test, Po10 16; odds ratio (OR) of 3.3; Fig. 1d and
Supplementary Fig. 5a). Similarly, we detected enrichment for
differentially expressed genes in the promoter interactions with
differential intensities between MKs and EBs (Fisher’s exact test,
Po10 16; OR 3.9; Supplementary Fig. 5b). Interestingly, the
differentially acetylated enhancers in either cell type are more
frequently located in the proximity of other differentially acety-
lated enhancers than expected by chance (Fisher’s exact test,
Po10 16; OR 7.3; Supplementary Fig. 5c).
SEs deﬁne MK and EB cell identities. To expand on this
observation of co-location of differentially acetylated elements, we
deﬁned SEs in both MKs and EBs, as these are considered the
drivers of cell type-speciﬁc gene expression. SEs are composed of
physically proximal enhancers (constituents) and have higher
than usual H3K27 acetylation and density of bound transcription
factors19–21. Using the analytical approach described in Whyte
et al.20, albeit not free from controversy especially for those
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enhancers close to the threshold22, we identiﬁed 1,067 and 1,287
SEs in MKs and EBs, respectively, 639 being shared (Fig. 2a,b,
Supplementary Fig. 6 and Supplementary Data 6). The remaining
enhancers with H3K27ac signals below the threshold (Fig. 2a,
Methods) were called other enhancers and their constituents
typical enhancers (TEs). We categorized genes according to the
number of interacting enhancers and observed that genes linked
to SE constituents had higher median expression than genes
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Figure 1 | Unique three-dimensional regulatory landscapes deﬁne megakaryopoiesis and erythropoiesis. (a) Top panel, MK ATAC-seq peak (126,428)
dynamics from HSCs through CMPs and MEPs, as well as EBs open chromatin as determined by DNase-seq (light green and grey, open and closed
chromatin, respectively). H3K27ac in CD34þ haematopoietic stem and progenitor cells (HSPCs, data from ROADMAP), enhancer regions (Enh) and
CTCF binding sites in MKs have been added for comparison (dark green, present). Categories: (I) Open chromatin regions present in all ﬁve cell types. In
MKs 24,318/47,502 (51.2%) of ATAC-seq peaks were CTCF-binding sites and 25,548/47,502 (53.8%) of these were enhancers. (II) Open chromatin
regions present from HSCs to MKs, but absent from EBs. (III) Open chromatin regions present either only in MKs or (IV) only in MKs and EBs. Bottom
panel, representative examples of open chromatin peaks for the four categories. (b) Categorization of elements based on differences in H3K27ac signal
intensities: black, nonsigniﬁcantly different (n¼B57,000); blue and red, signiﬁcantly higher in MKs (n¼ 6,810) and EBs (n¼ 5,237), respectively.
(c) Heatmap of 1,546 genes differentially expressed (DE) in RNA-seq analysis of MKs (left) and EBs (right). (d) Circular plot representing the interactions
between DE genes (MK-DE, light blue; EB-DE, red), differentially acetylated (DA) elements (MK-DA, green; EB-DA, brown) and differentially interacting
(DI) elements (MK-DI, dark blue; EB-DI, orange) on the outer arcs. Inner arc colours follow the same colour scheme and indicate overlap of attributes for
these categories. Connections reﬂect a concordance of fold changes: DE genes in MKs tend to interact with regions speciﬁcally acetylated in MKs
compared with EBs and vice versa.
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linked to TEs, across the categories and independently of the
constituent number (Fig. 2c, Supplementary Fig. 7a–c and
Supplementary Table 3). To determine when SEs in MKs
become activated, we used open chromatin data for the ﬁve
populations of blood progenitor cells and categorized the SE
constituent opening patterns during differentiation from HSCs to
MKs and EBs. This analysis showed that half of the SE
constituents in MKs overlapped open chromatin regions in
HSCs, two-thirds of which already had an H3K27ac mark in
CD34þ haematopoietic stem and progenitor cells (Fig. 2d and
Supplementary Data 7). However, only a small fraction of SEs
(24/1,067 and 45/1,287 in MKs and EBs, respectively) had all
their constituent enhancers open in HSCs and at the level of
CMPs and MEPs (Fig. 2d and Supplementary Fig. 7d,e).
Constituents that are in category I were also found to have a
higher number of PCHi-C interactions when compared with each
of the other categories (Wilcoxon test results in Supplementary
Fig. 7f,g legend). Thus, the control of genes determining the
distinct functional identities of MKs and EBs seems to be
achieved by the opening of just 2,125 (17.9%) and 2,263 (16.4%)
of SE constituents in MKs and EBs, respectively, at the ﬁnal stage
of differentiation (Supplementary Data 7).
Mapping platelet traits variants with functional genomics. Our
integrative analysis focused on 674 unique sentinel variants
associated with the CBC-P traits identiﬁed in our recent GWAS
in 173,480 individuals1. The majority (n¼ 565, 84%) of variants
are non-coding (intronic, intergenic or located in a promoter); 47
and 141 variants overlapped a promoter or enhancer in MKs,
respectively (Fig. 3a, Supplementary Fig. 8a and Supplementary
Data 8). Another 980 variants, from a set of 6,176 single-
nucleotide polymorphisms (SNPs) in linkage disequilibrium (LD;
r240.8; whole-genome sequencing data of 6,687 NIHR
BioResource—Rare Diseases samples) with sentinel variants,
were also located in enhancers (Fig. 3a). Interestingly, we
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Figure 2 | Identiﬁcation of SEs their effects on gene expression and their opening dynamics. (a) Schematic of the stitching process to identify enhancer
clusters and ranking based on H3K27ac signal intensities. (b) Overlap of SE sets in MKs and EBs. (c) Gene expression, in MKs, for genes connected to TEs
only (blue), SE constituents only (pink), or a combination of TEs and SE constituents (yellow) (box plot: line indicates median, upper and lower box margins
indicate ﬁrst and third quartile). Top row of schematic shows a gene regulated by ﬁve TEs, second row shows a gene regulated by ﬁve SE constituents and
the bottom rows show genes regulated by different combinations of ﬁve TEs and SE constituents. P-values for Wilcoxon test between different categories
are in Supplementary Table 3. (d) Opening dynamics of MK SEs constituents during HSC differentiation. Open chromatin regions overlapping with MK SE
constituents in HSCs, CMPs, MEPs and EBs. H3K27ac in CD34þ haematopoietic stem and progenitor cells (HSPCs) and CTCF-binding sites in MKs added
for comparison (colour legend as in Fig. 1a).
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observed a ﬁvefold enrichment of CBC-P sentinel variants located
in SE constituents relative to TEs in MKs (Fisher’s exact test,
Po2.2 10 16, OR 5.1). The successful assignment of the
coding and 75% of the non-coding CBC-P-associated variants
identiﬁed a set of 975 genes (Fig. 3b and Supplementary Fig. 8b
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Figure 3 | GWAS non-coding sentinel variants associated with platelet traits are enriched in SEs of MKs. (a) Categorization of sentinel variants
associated with CBC-P (count, mean volume, volume width distribution and platelet crit (mean volume count)) by location; exonic or splice site (light
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network of 4,235 nodes and 18,550 edges, which was generated by
using 781 of the 975 genes as baits to retrieve interactors). Only
205 variants (30%) were assigned solely to the nearest gene,
whereas 123 variants (18%) were assigned to the nearest gene and
additional genes, and 204 (30%) were linked to distal genes.
Indeed, the median distance of the new set of assigned genes to
associated variants was 88 kb compared with a median of 16 kb
for the gene set inferred by the coordinate-based approach still
widely used for the functional annotation of GWAS variants1
(Fig. 3c). The importance of having data on long-range
interaction between promoters and regulatory elements in a
relevant cell type was further illustrated by circular genomic
permutation analysis23 using the SEs and other enhancers in MKs
and EBs, respectively. This analysis showed that CBC-P-
associated variants, but not red cell ones, were more likely to
be located in MK-speciﬁc SEs and were less likely to be found in
other enhancers or in shared and EB-speciﬁc SEs (Fig. 3d and
Supplementary Table 4). The circular permutation analysis also
provided orthogonal evidence of qualitative differences between
the SE and TE.
Using interaction data, we linked the 1,067 SEs in MKs to 3,339
genes; SE-connected genes were enriched for the GO terms
haemostasis, degranulation and coagulation, which are arche-
typical for platelet function and thrombus formation
(Supplementary Data 6). These enrichments were even more
evident when only protein-coding genes connected to MK SEs
that harbour a CBC-P sentinel variant or proxy were considered,
as no other terms were found (Supplementary Fig. 8c and
Supplementary Data 9). To determine whether CBC-P-associated
loci also modulate the thrombotic function of platelets we tested
the CBC-P sentinel variants for association with quantitative
responses of platelets to activation by ADP and the collagen
mimetic CRP-XL in a cohort of just more than 1,200 genome-
wide typed healthy subjects24. Four CBC-P sentinel variants,
rs1613662 (GP6), rs12041331 (PEAR1), rs3557 (FCER1G) and
rs1354034 (ARHGEF3) were associated with at least one platelet
function trait at Po5 10 7.
SE variation and platelet functions. The variant rs3557 is located
in a SE interacting with the promoter of FCER1G, the gene
encoding the g-chain of the Fc receptor for IgE (Fig. 4a). This g-
chain also anchors the collagen signalling receptor glycoprotein
(GP)VI (encoded by GP6) in the membrane of platelets (Fig. 4b).
Here we replicate in a larger number of samples our earlier
ﬁndings24 that subjects carrying the minor allele of the non-
synonymous variant rs1613662 in GP6 have lower levels of
membrane GPVI and a concomitant reduced functional response
of their platelets to the GPVI-speciﬁc ligand CRP-XL (Fig. 4c,d).
We reasoned that, because of the functional association of GPVI
and the g-chain, variant rs3557 might also modify GPVI
abundance and GPVI downstream signalling events. Indeed,
when we tested these associations we observed that platelets of
subjects carrying the minor allele of the SE-located variant rs3557
have lower average GPVI levels and reduced average aIIbb3
integrin levels upon activation with CRP-XL (Fig. 4e,f). To
explore this further, we examined thrombus formation under
more physiological conditions (Supplementary Table 5). Platelets
become activated by collagen released from a ruptured plaque,
whilst being exposed to high shear. These conditions can be
mimicked ex vivo by ﬂowing whole blood over collagen-coated
surfaces in microchambers25. As expected, the blood from
subjects carrying the minor allele of rs1613662 (GP6) formed
thrombi to a lesser extent than the blood from subjects lacking
the minor allele (Fig. 4g). Unexpectedly, the association of rs3557
(FCER1G) with platelet activation by collagen III was of opposing
direction compared with the effect of the variant in the platelet
activation test with CRP-XL under static conditions
(P¼ 4.8 10 4; Fig. 4h). The opposite direction of the effects
is best explained by the differences between the synthetic collagen
mimetic CRP-XL, which only interacts with platelet GPVI versus
collagen III, which does in addition to GPVI also engages integrin
aIIbb1 and GPIba26.
We investigated a second example of a SE containing a CBC-P-
associated variant chosen, because in high LD (r240.96,
European ancestry subset of UK Biobank imputation data) with
the mean platelet volume (MPV)- (rs4991925) and platelet
distribution width (rs4290286)-associated variants identiﬁed in
Astle et al.1. The SNP rs2363877 is located in a MK-speciﬁc SE
interacting with the promoters of genes encoding the coagulation
protein, Von Willebrand factor (VWF) and the tetraspanin CD9
(Fig. 5a). VWF tethers platelets to the vessel wall via its receptor
GPIba but VWF’s functional role in thrombus formation cannot
be interrogated by the static platelet function tests and results
from microchamber tests would have been confounded by VWF
in plasma. We therefore used an alternative experimental
approach to determine the possible effects of the sentinel
variant rs2363877 on the regulation of the two genes. First, we
identiﬁed associations of opposing direction with the levels of
both VWF and CD9 proteins in platelets (Fig. 5b,c; Regression
coefﬁcient 0.163 (95% conﬁdence interval¼ 0.0821–0.243),
P¼ 10.0 10 5 and regression coefﬁcient  1.1 (95%
conﬁdence interval ¼  2.3–1.0), P¼ 1.3 10 6, respectively).
Second, to characterize the mechanism by which the SE
containing rs2363877 exerts its action on gene transcription, we
used CRISPR/Cas9 to knock out part of the element in an
induced pluripotent stem cell (iPSC) clone (Fig. 5a, black bar). In
MKs obtained by forward programming27 of genome-edited
iPSCs, we observed an effect on the transcript levels of both genes
in the same direction as the minor allele of rs2363877, with a
Figure 4 | Association between SE-localized sentinel variant rs3557 and thrombus phenotypes. (a) Chr1 1q23.3 locus view comprising FCER1G and three
other genes. From top to bottom: H3K27ac signal track and SE location in MKs (blue) and EBs (red); *position of sentinel variant rs3557 and genes in green.
Scale bar in bottom right corner represents 2 kb. Maximum read signal scale 60 for each track. (b) Schematic representation of the glycoprotein (GP)VI/Fc
receptor g-chain signalling receptor complex for collagen on platelets. (c–h) Associations of genotypes of rs1613662 and rs3557 with the residuals of
platelet function phenotypes, after adjustment for covariates. Dots show distribution of the phenotypic residuals; central lines show genotype-speciﬁc mean
estimates and whiskers represent 95% conﬁdence intervals. (c,e) Associations with platelet membrane level of GPVI after linear adjustement for the
interaction of logged mean platelet volume and sex (rs1613662: GG¼ 36, GA¼ 221, AA¼ 587, likelihood ratio additive P¼ 1.6 10 27; rs3557, TT¼ 696,
TG¼ 139, GG¼9, likelihood ratio additive P¼4.6 10 5). (d,f) Associations of ﬁbrinogen binding to integrin aIIbb3 after platelet activation with CRP-XL,
adjusted for sex (rs1613662: GG¼49, GA¼ 381, AA¼992, likelihood ratio additive P¼ 1.6 10 7; rs3557, TT¼ 1,175, TG¼ 229, GG¼ 18, likelihood ratio
additive P¼4.6 10 72). (g,h) Associations for rs1613662 and rs3557 with thrombus formation upon ﬂowing whole blood over collagen III in
microchambers, measured by quantile-normalized sex-adjusted platelet surface area coverage (PltSac; GG¼ 1, GA¼ 29, AA¼63, likelihood ratio additive
P¼ 1.8 10 2) and quantile-normalized sex-adjusted activation of integrin aIIbb3 (ITG; TT¼ 67, TG¼ 24, GG¼ 2, likelihood ratio additive
P¼ 3.4 10 3), respectively.
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Figure 5 | Effect of the SE-localized platelet trait associated sentinel variant rs2363877 on VWF and CD9 protein abundance. (a) Chr12p13.31 locus
view comprising VWF, CD9 and two other genes. From top to bottom: H3K27ac signal track and SE locations in MKs (blue) and EBs (red). Region of SE
deleted by genome-editing (black); positions of sentinel variant rs2363877(*) and genes (green). Scale bar in bottom right corner represents 10 kb.
Maximum read signal scale 60 for each track. (b,c) Associations of variant rs2363877 with (b) concentration of VWF in platelets (Y axis ng ml 1
normalized against total protein content; for subjects of genotypes: GG, n¼ 20; GA, n¼47; AA, n¼ 26; likelihood ratio, P¼ 10.0 10 5) and (c) CD9
abundance on platelet surface (y axis mean ﬂuorescence intensity (MFI) adjusted for mean platelet volume; for subjects of genotypes: GG, n¼ 122; GA,
n¼ 165; AA, n¼ 78; likelihood ratio, P¼ 1.3 10 6). Lines indicate mean, whiskers indicate 95% conﬁdence interval. (d) Transcript levels of VWF and CD9
in MKs obtained by forward programming of wild type and genome-edited pluripotent stem cells (n¼ 3 biological replicates each in triplicate; error bars
generated from s.e. calculated from delta Ct value across technical and biological replicates, Student’s t-test *P¼ 2.2 10 2 and ***P¼ 5.0 104).
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near-complete absence of the CD9 transcript (Fig. 5d). The results
of these experiments are compatible with the notion that the SE
has both enhancing and repressive effects on the transcription of
CD9 and VWF, respectively. We assume that the different levels
of VWF and CD9 proteins of platelets may modify the extent of
thrombus formation and integrin signalling.
Discussion
Altogether we found that just more than 32% of CBC-P-
associated non-coding sentinel variants are located in enhancer
elements or promoters of MKs and 423 (75%) of non-coding
variants can now be linked with high conﬁdence to the genes they
regulate. The sentinel variants are enriched in MK SEs, which are
often absent from EBs, thereby explaining in part the observation
that most sentinel variants associated with platelet traits do not
have an effect on red cell traits. Microchamber experiments and
the use of genome-editing of iPSCs illustrate the role of SEs in the
regulation of thrombus formation and the transcription of distant
genes with important roles in haemostasis. Moreover, sentinel
variants localized in SEs can have an effect on more than one
gene highlighting the importance of genome conformation
experiments to improve understanding of the molecular pathways
underlying complex traits.
Methods
Puriﬁcation of progenitor cell populations. Peripheral blood mononuclear cells
were isolated using Ficoll-Paque gradients from apheresis ﬁlters, obtained from
platelet donors after informed consent (A Blueprint of blood cells, REC 12/EE/
0040, East of England-Hertfordshire Research Ethics committee). Progenitor cell
populations were enriched by positive selection using CD34þ magnetic beads
(130-046-702, Miltenyi) and puriﬁed by FACS sorting using a BD FACS Aria III.
Progenitor cells were stained for ﬂow cytometry analysis as previously described in
Chen et al.2 and Supplementary Fig. 1 legend.
Cord blood-derived MKs and EBs. Human cord blood was obtained after
informed consent (A Blueprint of blood cells, REC 12/EE/0040, East of England-
Hertfordshire Research Ethics committee), and MKs and EBs were generated
through differentiation of CD34þ cord blood-derived cells as described in Chen
et al.2.
ATAC-seq libraries. Assay for transposase-accessible chromatin with high
throughput sequencing (ATAC-seq) libraries were generated from freshly prepared
cells using the protocol by Buenrostro et al.28. For MKs, 105 cells were used with
ten ampliﬁcation cycles. For HSCs, CMPs and MEPs, 104 cells were used with 12
ampliﬁcation cycles. Libraries were quantiﬁed using a quantitative PCR (qPCR)
Library Quantiﬁcation Kit (Kapa Biosystems), pooled and sequenced with a 50 bp
single-end protocol on an Illumina Hiseq 2,500.
RNA-seq libraries. RNA sequencing (RNA-seq) libraries were generated by the
BLUEPRINT Consortium. In brief, RNA was extracted from TRIzol preparations
by phase-separation and precipitation. One microgram of DNase-treated RNA was
used to generate ribosomal RNA-depleted libraries with a TruSeq Stranded Total
RNA Library Prep Kit (with Ribo-Zero Human/Mouse/Rat, RS-122-2201, Illu-
mina). Libraries were quantiﬁed using a qPCR Library Quantiﬁcation Kit (Kapa
Biosystems), pooled and sequenced using paired-end 76 bp sequencing on an
Illumina Hiseq 2000.
ChIP-seq libraries. Samples were ﬁxed and prepared using the BLUEPRINT
Consortium protocol. In brief, cells were ﬁxed with 1% w/v formaldehyde for
10min and quenched using 125mM glycine before washing with PBS. Samples
were sonicated using a Bioruptor (Diagenode), ﬁnal SDS concentration of 0.1% w/v
for 9 cycles of 30 s ‘on’ and 30 s ‘off’, and immunoprecipitated using an IP-Star
Compact Automated System (Diagenode). For H3-speciﬁc antibodies the Auto-
Histone ChIP-seq kit protein A (Diagenode) and for CTCF antibody the Auto
iDeal ChIP-seq Kit for Transcription Factors (Diagenode) were used with Diag-
enode antibodies listed in Supplementary Table 6.
Immunoprecipitated and input DNA were reverse cross-linked (65 C for 4 h),
treated with RNase and Proteinase K (65 C for 30min). DNA was recovered with
Concentrator 5 columns (Zymo) and prepared for sequencing using MicroPlex
Library Preparation Kit v2 (Diagenode). Libraries analysed using High Sensitivity
Bioanalyzer chips (5,067–4,626, Agilent), quantiﬁed using qPCR Library
Quantiﬁcation Kit (Kapa Biosystems), pooled and sequenced with a 50 bp single-
end protocol on an Illumina Hiseq 2500.
Platelet function analysis. This is an interim analysis of the Cambridge Platelet
Function Cohort and the discrepancies between numbers of test for each agonist
tested depend on when the assay was introduced. Platelet function testing and data
analysis were performed as described in Jones et al.24 in up to 1,500 individuals by
investigators blind to the tested subject genotype. For details please refer to
Supplementary Information.
VWF quantiﬁcation in platelet lysates and plasma. VWF was quantiﬁed by
ELISA; for details please refer to Supplementary Information.
CD9 measurement on platelet surface. The surface expression of CD9 was
measured, by using ﬂow cytometry, in platelet rich plasma (PRP) of 365 healthy
subjects, part of the Cambridge Platelet Function Cohort, by investigators blind to
the subjects’ genotype. For details, please refer to Supplementary Information.
VWF and CD9 genotype–phenotype associations. TaqMan assays (Applied
Biosystems) were used to genotype whole-blood DNA extracted from the NIHR
Cambridge BioResource volunteers using the manufacturer’s protocol. NHSBT
blood donors were genotyped using Illumina genome wide typing array followed
by imputation. To identify CD9 and VWF genotype–phenotype associations, we
used linear regression models and tested for associations using likelihood ratio
tests. Samples were excluded only if genotyping failed. A sample size of B100
individuals has been deemed sufﬁcient to determine the extent of VWF and CD9
measured variation in platelet, given our assay sensitivities24,25 and rs2363877 allele
frequency.
Human iPSCs. A1ATD-1 iPSCs were cultured at 37 C with 5% CO2 using
Vitronectin (Life Technologies) treated plates and AE6 Media (DMEM/F12,
Thermo Fisher), 0.05% w/v Sodium Bicarbonate (Thermo Fisher), 64.1 mgml 1 L-
Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma), 1 Insulin-
Transferrin-Selenium (Thermo Fisher); supplemented with 15 ngml 1 FGF2
(Cambridge Stem Cell Institute) and 15 ngml 1 Activin A (Cambridge Stem Cell
Institute).
Genome editing of VWF-CD9 SE by CRISPR-Cas9. A 22 kb region located at one
end of the VWF-CD9 SE 1 containing rs2363877 was knocked out (Fig. 5a, black
bar). Single-guide RNAs (sgRNAs) were designed at either side of the target region
(sgRNA1 and sgRNA2, Supplementary Table 7) using Protospacer WB software.
Both strands were synthesized (IDT) with overhangs for ligation with BbsI sites of
SpCas9-2A-Puro V2.0 (Addgene). To prepare SpCas9-2A-Puro V2.0, 1 mg was
digested with 10U of BbsI (NEB) for 1 h at 37 C. Double-strand sgRNA1 and
sgRNA2 oligonucleotides were ligated into the linearized plasmid using 600U of
T4 DNA ligase (NEB) for 1 h at 37 C. Ligation products were transformed into
competent a-Select Gold Efﬁciency Cells (Bioline) and plated on LB-agar ampi-
cillin (100 mgml 1) plates. Plasmids were veriﬁed by Sanger sequencing with U6-
Forward Primer: 50-GAGGGCCTATTTCCCATGATTCC-30 . Plasmid puriﬁcation
for nucleofection was performed using EndoFree Plasmid Maxi Kit (Qiagen)
according to the manufacturer’s protocol. iPSCs were pre-treated with 10 mM
ROCK inhibitor (Y-27632, Sigma) 4 hours before nucleofection, washed once with
DPBS and incubated with Accutase (Thermo Fisher) for 5 minutes at 37 C. Cells
were dissociated into clumps of three to four cells and counted. Then 2 106 cells
were suspended in 100 ml of nucleofection P3 solution (Lonza) and electroporated
with 8 mg of sgRNA1 and sgRNA2 expression vectors. Electroporation was per-
formed using the 4D-Nucleofector System (Lonza) with the nucleofection program
CA 137. Electroporated cells were plated onto 10 cm Vitronectin-coated plates in
TeSR-E8 medium containing 10 mM ROCK inhibitor and incubated at 37 C under
5% CO2. Puromycin selection (1 mgml 1) commenced 24 h post nucleofection for
48 h. TeSR-E8 medium was changed daily. After 14 days single colonies were
picked, expanded and genotyped (oligonucleotides described in Supplementary
Table 8). Homozygous SE knockout (KO) iPSCs were generated at 15% efﬁciency.
Forward programming of iPSC to MKs. A1ATD-1 iPSCs were forward pro-
grammed into MKs using the adherent cell protocol described Moreau et al.27.
Cells were stained with CD41a-APC and CD42b-PE antibody conjugates (BD) and
sorted using the FACS Aria Fusion (BD) FACS instrument.
Gene expression in KO iPSCs using quantitative real-time PCR. Quantitative
real-time PCR (qRT–PCR) was performed on complementary DNA generated
from the forward programmed iPSC cell lines (A1ATD-1). The investigator per-
forming the assay was aware of the genotype of the samples. Exon spanning
oligonucleotides (Supplementary Table 9) were used to detect VWF, CD9 and the
control gene GUSB.
qRT–PCR reactions used Brilliant II SYBR Green QPCR Master Mix (Agilent
Technologies) and conditions: 95 C, 5min; 40 cycles of 95 C, 30 s; 60 C, 30 s and
72 C, 30 s. Three iPSC lines of wild type and KO were tested (biological replicates)
and qRT–PCR was performed in triplicate (technical replicates). Relative gene
expression was presented as mean delta Ct against the reference and scaled so the
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wild-type expression levels of each gene were equal; error bars were generated from
the s.e. calculated from the delta Ct values across technical and biological replicates.
t-tests were used to analyse differences of the mean delta Ct values.
Multimodular platelet activation in thrombus formation. Citrate-anticoagulated
blood was used for multivariate platelet function analysis, using a microspot-based
whole-blood microﬂuidics ﬂow assay25,29. For details, please refer to
Supplementary Information.
RNA-seq analysis. Trim Galore 0.3.7 (http://www.bioinformatics.babraham.a-
c.uk/projects/trim_galore/) with parameters ‘-q 15 -s 3 --length 30 -e 0.05’ was used
to trim PCR and sequencing adapters. Trimmed reads were aligned to the Ensembl
v70 (ref. 30) human transcriptome with Bowtie 1.0.1 (ref. 31), with parameters ‘-a
--best --strata -S -m 100 -X 500 --chunkmbs 256 --nofw -fr’. MMSEQ 1.0.8a
(refs 32,33), and was used with default parameters to quantify gene expression.
Genes with posterior probability40.5 (calculated by MMDIFF), absolute fold
change 42 and fragments per kilobase of transcript per million mapped reads
(FPKM) 41 in at least one of the two cell types were considered differentially
expressed.
ChIP-seq analysis. We applied the BLUEPRINT protocol for chromatin immu-
noprecipitation sequencing (ChIP-seq) data analysis: http://dcc.blueprint-epigen-
ome.eu/#/md/chip_seq_grch37.
CTCF peak calling. A cell-type-speciﬁc input was created by merging biological
replicates into a single alignment ﬁle with ‘samtools merge’34,35. Peak calling was
performed using MACS2 (ref. 36) (https://github.com/taoliu/MACS) after
randomly down-sampling the input to the same number of reads in the
corresponding sample and removing duplicates with PICARD tools (https://
broadinstitute.github.io/picard/). To identify a set of reproducible CTCF peaks
between the two EB replicates we used the irreproducible discovery rate analysis
(https://sites.google.com/site/anshulkundaje/projects/idr). The maximum
combined corrected P-value upon application of an irreproducible discovery rate
threshold of 0.01 was used as a cutoff, to ﬁlter the CTCF MACS2 peaks called in the
single-replicate MK sample. In total, we identiﬁed 38,326 CTCF peaks and 42,344
CTCF peaks in EB and MK, respectively.
Genome segmentation. To identify genomic segments of recurring signal patterns
across a set of six histone modiﬁcations (H3K4me1, H3K4me3, H3K9me3,
H3K27ac, H3K27me3 and H3K36me3) in EBs and MKs, we used the genome
segmentation algorithm IDEAS18. IDEAS jointly segments the genome across
multiple cell types and infers the optimal number of distinct signal patterns, called
states. We generated smoothened and normalized genome-wide signal per histone
modiﬁcation per cell type in bigwig format using align2rawsignal (https://
github.com/akundaje/align2rawsignal) on two biological replicates. Then we used
WiggleTools37 to count the mean number of reads per 200 bp bins across the
genome. Finally, IDEAS identiﬁed 30 distinct states that were used to classify each
200 bp bin across genome in both cell types to one of these states. Each state was
manually assigned a functional label, using as a guide the functional label
assignment from Ernst et al.38. The 11 functional labels were as follows: inactive,
heterochromatin, Polycomb repressed, transcribed, enhancer, bivalent enhancer,
enhancer tail, promoter, weak promoter, bivalent promoter and promoter tail.
CTCF enrichment in network elements. PCHi-C was performed using the
restriction endonuclease HindIII16. Restriction fragments were overlapped with
CTCF peaks in MKs and EBs. Restriction fragments overlapping ENCODE
blacklisted regions (https://www.encodeproject.org/annotations/ENCSR636HFF/))
were removed. All remaining fragments were then overlapped with all connected
baits as well as interacting regions (preys) in the respective cell types. A zero-
inﬂated negative binomial regression on the peak counts per fragment was
calculated on the number of interactions per fragment, accounting for the fragment
length as logarithmic offset. The number of interactions was calculated for each
fragment by counting to how many other fragments it was connected, using a
CHiCAGO PCHi-C interaction score threshold of at least 5 (ref. 39).
Open chromatin data analysis. EB DNase-seq data were obtained from Kellis
et al.40 (GEO accession numbers GSE55579, GSM1339559 and GSM1339560). Raw
Illumina DNase-seq reads were trimmed for quality using TrimGalore! v0.3.7 with
a Phred score cut off of 15 (-q 15) (www.bioinformatics.babraham.ac.uk/projects/
trim_galore/). MK, HSC, CMP and MEP ATAC-seq reads underwent quality and
adapter trimming using TrimGalore! v0.3.7 with parameters -q 15 --stringency 3 -a
50-CTGTCTCTTATACACATCTCTGA-30. We followed the BLUEPRINT
protocol for alignment of DNase-seq and ATAC-seq reads to GRCh37 using BWA
and ﬁltering of alignments (http://dcc.blueprint-epigenome.eu/#/md/
dnase_seq_grch37) as well as for modelling fragment length with SPP41 and
producing signal plots with align2rawsignal (http://dcc.blueprint-epigenome.eu/#/
md/chip_seq_grch37) using the triweight smoothing method. Bedgraph ﬁles were
converted to bigwig using bedGraphToBigWig42 (https://www.encodeproject.org/
software/bedgraphtobigwig). Open chromatin peaks were called with F-seq43 with
fragment size (-f) at 0 and the ‘s.d. threshold’ (-t) at 6. We removed peaks
overlapping ENCODE blacklisted regions (https://www.encodeproject.org/
annotations/ENCSR636HFF/) using bedtools v2.22.0 (ref. 44). For open chromatin
data with two replicates, we called peaks separately, and retained and merged peaks
present in both replicates (minimum overlap 1 bp) using bedtools merge.
Open chromatin dynamics. We traced back the opening of MK ATAC-seq peaks
(Fig. 1a, Supplementary Fig. 2a) and EB DNaseI-seq peaks (Supplementary Fig. 2b)
by overlapping with ATAC-seq peaks called in HSCs, CMPs and MEPs (minimum
overlap of 1 bp). CTCF labels were assigned based on overlap with CTCF peaks
obtained in the corresponding cell type (MKs or EBs). Enhancer labels were
assigned by overlapping open chromatin peaks±500 bp (to account for the shift
between the open chromatin signal and the H3K27ac signal) with enhancers in MK
or EB as identiﬁed by genome segmentation.
To determine which peaks had an H3K27ac signature in CD34þ cells, we used
the consolidated epigenome ﬁle for H3K27ac and the corresponding input from
ROADMAP Epigenomics (http://egg2.wustl.edu/roadmap/web_portal/
processed_data.html). We converted the tagAlign ﬁles to bam ﬁles with bedtools
v2.22.0, bedToBam and called peaks using MACS2 with the same parameters as
used for CTCF peak calling. We overlapped open chromatin peaks±500 bp with
the CD34þ H3K27ac peaks.
Deﬁning SEs. SEs in MKs and EBs were called based on regions identiﬁed as
enhancers in the IDEAS genome segmentation (71,477 and 71,406 regions in MKs
and EBs, respectively). We removed regions overlapping promoter, weak promoter
and bivalent promoter states±1 kb to avoid confounding of enhancer and pro-
moter H3K27ac signals. The remaining 52,929 enhancers for MKs and 54,944
enhancers for EBs were stitched together, if enhancers were within 12.5 kb, using
ROSE (Fig. 2a, top panel)19,20,45. Stitched enhancers and single enhancers were
ranked based on H3K27ac signal (merged from two biological replicates) after
removing alignments within promoter regions and ENCODE blacklisted regions
from the H3K27ac bam ﬁle and the corresponding ChIP-seq input (Fig. 2a bottom
panel and Supplementary Fig. 6a). We identiﬁed 1,067 SEs in MKs (shown in pink
in Fig. 2a), made up of 11,860 SE constituents, and 17,790 other enhancers (shown
in blue in Fig. 2a), made up of 41,069 IDEAS enhancers (TEs). In EBs we identiﬁed
1,287 SEs (shown in pink in Supplementary Fig. 6a), made up of 13,811
constituents, and 17,954 other enhancers (shown in blue in Supplementary Fig. 6a),
made up of 41,133 TEs. Overlaps between EB and MK SEs were determined with
bedtools v2.22.0 requiring at least 50% of their length to overlap.
SE opening. We traced the opening of SEs by overlapping SE constituents with
MK ATAC-seq or EB DNaseI-seq open chromatin peaks±500 bp. These MK or
EB open chromatin peaks were overlapped with ATAC-seq peaks in HSCs, CMPs
or MEPs (minimum overlap of 1 bp). CTCF and CD34þ H3K27ac labels were
assigned as described above for chromatin opening.
Differentially acetylated enhancers. To identify differentially acetylated
enhancers between MKs and EBs, we used the DiffBind R package (Bioconductor
http://bioconductor.org/packages/release/bioc/html/DiffBind.html), using as input
the MK and EB enhancer regions identiﬁed using IDEAS genome segmentation
algorithm and the alignments of H3K27ac and input per cell type (two biological
replicates each). The tool collapsed the two sets of enhancers to 68,672 enhancer
regions and then counted the number of reads overlapping each region. Sample
normalization and differential analysis were then performed using DESeq2
(ref. 46). Figure 1b displays an MA plot for all enhancer regions, highlighting the
differential acetylated regions; adjusted P-valueo0.05 and an absolute log2 fold
change41.
Detection of cell type-speciﬁc promoter-interacting regions. The differentially
interacting fragments between MKs and EBs were identiﬁed using the DESeq2 R
package (Bioconductor, https://bioconductor.org/packages/release/bioc/html/
DESeq2.html). Interactions with a normalized CHiCAGO score of at least 5 in at
least one of the two cell types were tested with standard parameters.
Region annotation based on PCHi-C. All HindIII fragments captured in the
PCHi-C (baits) were annotated with the genes whose transcriptional start sites they
overlapped (Ensembl v70). Enhancers, SEs and open chromatin peaks were
assigned to the genes they interact with using PCHi-C data of the corresponding
cell type16 by overlapping the region of interest with all possible HindIII fragments
of the human genome. Regions of interest overlapping prey HindIII fragments were
assigned to an interacting gene if an interacting bait fragment contained the
promoter region of that gene. Interactions were also considered between two bait
HindIII fragments. Interactions between a bait fragment containing the region of
interest and a prey fragment were not considered. For baits that contain
transcriptional start sites for more than one gene, all overlapping genes were used
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16058
10 NATURE COMMUNICATIONS | 8:16058 | DOI: 10.1038/ncomms16058 | www.nature.com/naturecommunications
to deﬁne the interacting gene. If the region of interest overlapped with more than
one HindIII fragment and/or interacted with more than one bait, interactions of all
overlapping fragments and all interacting baits were used. A total of 674 GWAS
sentinel SNPs for mean platelet volume, platelet count, platelet distribution width
and plateletcrit from Astle et al.1, were assigned to the gene(s) they most probably
inﬂuence in a multi-step process (Supplementary Fig. 8a):
– Based on the VeP prediction47, exonic and splice site variants were assigned
to the corresponding gene.
– Variants overlapping exons of genes that were not expressed in our RNA-seq
data (FPKMo1) and non-coding variants were overlapped with MK
promoters±1 kb that overlap an annotated transcriptional start site (as
obtained from the genome segmentation) and assigned to the corresponding
gene(s).
– If an exonic GWAS sentinel SNP was in an element labelled as an enhancer in
the IDEAS genome segmentation or if the gene was not expressed in our
RNA-seq data (FPKMo1), and the SNP did not overlap a promoter, the
variant was assigned to the gene and additionally to the gene(s) of the
interacting PCHi-C bait(s).
– Intronic and intergenic variants were overlapped with HindIII fragments and
assigned to the genes of the baits interacting with the overlapping fragment.
If there was no interacting bait, we obtained all variants in LD (r2¼ 1) from the
NIHR BioResource—Rare Diseases whole genome sequencing and whole exome
sequencing study (https:/bioresource.nihr.ac.uk/rare-diseases/welcome/) of 6,687
subjects, repeated our annotation steps with this set of variants and used their
annotations as the sentinel SNP annotation.
We repeated these steps for unassigned variants identifying variants at r2Z0.9
in the ﬁrst instance and subsequently at r2Z0.8. Variants that could not be
assigned by LD, either because they had no LD variants or because the LD variants
could not be assigned, were assessed for overlap with PCHi-C baits±10 kb and
assigned to the gene(s) on the overlapping bait as we know that we lack sensitivity
to detect short-range interactions between promoters and regulatory elements16.
GO term enrichment. FIDEA was used to determine enrichment of GO terms in
gene lists48.
Protein–protein interaction network. The proteins encoded by the 781 protein-
coding genes assigned to a GWAS variant based on PCHi-C and LD data were used
as primary baits to develop the protein–protein interaction network and the cor-
responding UNIPROT protein identiﬁer was obtained. To develop a system level
network centered on the core proteins, we initially searched for ﬁrst-order inter-
actors of the 781 core proteins in public databases. Two different types of resources
were used for this initial effort, Reactome49 (www.reactome.org) and IntAct50
(http://www.ebi.ac.uk/intact/) databases. Network visualization was done using
Cytoscape51 (http://www.cytoscape.org/).
CBC-P GWAS hit circular permutation enrichment in regulatory regions. The
signiﬁcance of enrichment of strongly associated GWAS variants in SE was esti-
mated by the circular permutation method. The number of variants signiﬁcantly
associated with platelet traits and residing within SEs was determined. Then
P-values for all variants in the GWAS study were shifted forward by a random
number of variant positions (when an end of a chromosome was reached P-values
were moved to next chromosome; chromosome one was assumed to follow
chromosome 22). The P-values were thus shifted 999,999 times and on each
occasion SEs were overlaid with signiﬁcant associations (altered P-values were
considered when locating strong associations after a shift). P-values measuring how
likely it is to see at least the number of observed variants within SEs were obtained
for both original and shifted data sets. The latter P-values were ranked and the rank
of the original data set was determined; this rank was divided by 1,000,000 and was
reported as an empirical P-value. Within each enrichment, the number of platelet
variants in SEs was contrasted with the amount of red cell variants residing within
the same type of SEs. SEs of another cell type were used to model the background
distribution of signiﬁcant GWAS variants within enhancers. Thus, an enrichment
is always relative to other enhancers and is estimated as an enrichment of platelet
trait variants versus red cell variants. The same procedure was carried out for other
enhancer types—the foreground and background enhancers were exchanged,
whereas the sets of platelet and red cell variants stayed the same. The method of
shifting P-values preserves correlations between nearby variants and is also well
suited for dealing with physical clustering of enhancer regions on genome.
The numbers of various types of variants within diverse enhancer regions are
summarised in Supplementary Table 10.
Data availability. BLUEPRINT ChIP-seq data for MKs and EBs were obtained
from EGA data sets EGAD00001002362 and EGAD00001002377, respectively.
BLUEPRINT RNA-seq data were obtained from EGA study EGAS00001000327.
All additional high-throughput sequencing data used in this manuscript have been
deposited in EGA under data set EGAD00001001871.
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